0000000000310250

AUTHOR

Erberto Carluccio

showing 3 related works from this author

Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-AR…

2021

Abstract Aims This sub-study deriving from a multicentre Italian register [Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry (DISCOVER)-ARNI] investigated whether sacubitril/valsartan in addition to optimal medical therapy (OMT) could reduce the rate of implantable cardioverter-defibrillator (ICD) indications for primary prevention in heart failure with reduced ejection fraction (HFrEF) according to European guidelines indications, and its potential predictors. Methods and results In this observational study, consecutive patients with HFrEF eligible for sacubitril/valsartan from 13 Italian centres were included. Lack o…

Left ventricular strainHeart failure; Implantable cardioverter-defibrillator; Left ventricular strain; Remodelling; Sacubitril/valsartanRemodellingHeart failureSacubitril/valsartanHeart failure Implantable cardioverter-defibrillator Left ventricular strain Remodelling Sacubitril/valsartanImplantable cardioverter-defibrillator
researchProduct

Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry

2022

Aims: Sacubitril/valsartan has changed the treatment of heart failure with reduced ejection fraction (HFrEF), due to the positive effects on morbidity and mortality, partly mediated by left ventricular (LV) reverse remodelling (LVRR). The aim of this multicenter study was to identify echocardiographic predictors of LVRR after sacubitril/valsartan administration. Methods and results: Patients with HFrEF requiring therapy with sacubitril/valsartan from 13 Italian centres were included. Echocardiographic parameters including LV global longitudinal strain (GLS) and global peak atrial longitudinal strain by speckle tracking echocardiography were measured to find the predictors of LVRR [= LV end-…

EchocardiographyUltrasoundRemodellingHeart failureSacubitril/valsartanBiomarkers Cardiovascular disease Echocardiography Heart failure Imaging Remodelling Sacubitril/valsartan Speckle tracking UltrasoundCardiology and Cardiovascular MedicineCardiovascular diseaseBiomarkers; Cardiovascular disease; Echocardiography; Heart failure; Imaging; Remodelling; Sacubitril/valsartan; Speckle tracking; Ultrasound.BiomarkersImagingSpeckle tracking
researchProduct

Effects of SGLT2 inhibitors on cardiac structure and function.

2022

SGLT2 inhibitors reduce cardiovascular death or hospitalization for heart failure, regardless of the presence or absence of diabetes in patients at high cardiovascular risk and in those with heart failure and reduced ejection fraction (HFrEF). In patients with HF and preserved EF, empagliflozin also showed favorable effects mainly related to the reduction of hospitalization for heart failure. These favorable effects are beyond the reduction of glycemic levels and mainly related to beneficial hemodynamic and anti-inflammatory effects of these drugs and improved cardiac energy metabolism. In this review, we aimed to evaluate the effects of SGLT2 inhibitor on cardiac remodeling and function, w…

Ejection fractionDiastolic functionSystolic functionHeart failureLeft ventricleCardiology and Cardiovascular MedicineSGLT2 inhibitorsCardiac remodelingHeart failure reviews
researchProduct